NHS England updates CDF List
NHS England updates CDF List
NHS England has updated the Cancer Drugs Fund List. The latest version (v1.375) was uploaded to the NHS England Website on Tuesday 7, October 2025.
The following changes have been introduced:
Lorlatinib monotherapy (LOR2)
Lorlatinib monotherapy for anaplastic lymphoma kinase-positive advanced non- small cell lung cancer previously untreated with an ALK inhibitor where the following criteria have been met
Recommended for routine commissioning, receiving CDF interim funding
NA (NHSE Urgent Interim)
NA
Removed from CDF weblist
Alectinib monotherapy (ALE1)
For anaplastic lymphoma kinase-positive advanced non-small cell lung cancer previously untreated with an ALK inhibitor where the following criteria are met:
Drug column updated; Treatment criterion (#4) updated; Treatment criteria (#8 and 10) removed
Brigatinib monotherapy (BRI2)
For anaplastic lymphoma kinase-positive advanced non-small cell lung cancer previously untreated with an ALK inhibitor where the following criteria have been met
Drug column updated; Treatment criterion (#4) updated; Treatment criteria (#8, 9 and 11) removed
Durvalumab (DUR7)
Durvalumab monotherapy for patients with limited- stage small cell lung cancer whose disease has not progressed following platinum-based chemoradiotherapy where the following criteria have been met
Treatment criterion (#7) and date moving into routine commissioning updated
Isatuximab in combination with bortezomib, lenalidomide, and dexamethasone (ISA2)
in combination (with bortezomib, lenalidomide, and dexamethasone) for the treatment of UNTREATED multiple myeloma when a stem cell transplant is UNSUITABLE where the following criteria have been met
Date moving into routine commissioning updated